FDA ANDA · ANDA090753

SUMATRIPTAN; NAPROXEN SODIUM

Sponsor: PAR PHARM

APPLICATION

ANDA090753

TYPE

ANDA

ROUTE

ORAL

DOSAGE FORM

TABLET

MARKETING STATUS

None (Tentative Approval)

Products

SUMATRIPTAN; NAPROXEN SODIUMNone (Tentative Approval)

SUMATRIPTAN 85MG, NAPROXEN SODIUM 500MG · TABLET · ORAL

2013-11-29OriginalTA

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.